EA202190902A1 - Ингибирование синтазы жирных кислот (fasn) - Google Patents

Ингибирование синтазы жирных кислот (fasn)

Info

Publication number
EA202190902A1
EA202190902A1 EA202190902A EA202190902A EA202190902A1 EA 202190902 A1 EA202190902 A1 EA 202190902A1 EA 202190902 A EA202190902 A EA 202190902A EA 202190902 A EA202190902 A EA 202190902A EA 202190902 A1 EA202190902 A1 EA 202190902A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fasn
fatty acid
acid synthase
synthase inhibition
inhibition
Prior art date
Application number
EA202190902A
Other languages
English (en)
Inventor
Мэттью В. Мартин
Мэри-Маргарет Заблоцки
Скот Мент
Кристофер ДИНСМОР
Чжунго Ван
Сяочжан Чжэн
Original Assignee
Форма Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Форма Терапьютикс, Инк. filed Critical Форма Терапьютикс, Инк.
Priority claimed from PCT/US2019/055603 external-priority patent/WO2020077071A1/en
Publication of EA202190902A1 publication Critical patent/EA202190902A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Данное описание направлено на ингибиторы FASN. Данные соединения могут быть пригодны в лечении заболевания или расстройств, связанных с ингибированием FASN. Например, данное описание касается соединений и композиций для ингибирования FASN, способов лечения, предупреждения или облегчения заболеваний или расстройств, связанных с ингибированием FASN, и способов синтеза данных соединений.
EA202190902A 2018-10-10 2019-10-10 Ингибирование синтазы жирных кислот (fasn) EA202190902A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744071P 2018-10-10 2018-10-10
TW108136774A TWI767148B (zh) 2018-10-10 2019-10-09 抑制脂肪酸合成酶(fasn)
PCT/US2019/055603 WO2020077071A1 (en) 2018-10-10 2019-10-10 Inhibiting fatty acid synthase (fasn)

Publications (1)

Publication Number Publication Date
EA202190902A1 true EA202190902A1 (ru) 2021-09-17

Family

ID=70159790

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190902A EA202190902A1 (ru) 2018-10-10 2019-10-10 Ингибирование синтазы жирных кислот (fasn)

Country Status (14)

Country Link
US (3) US10875848B2 (ru)
JP (1) JP2022504730A (ru)
KR (1) KR20210075120A (ru)
CN (1) CN113329748A (ru)
AR (1) AR116626A1 (ru)
AU (1) AU2019357592A1 (ru)
BR (1) BR112021005836A2 (ru)
CA (1) CA3116045A1 (ru)
EA (1) EA202190902A1 (ru)
IL (1) IL282065A (ru)
MA (1) MA51606A (ru)
MX (1) MX2021003992A (ru)
SG (1) SG11202103454SA (ru)
TW (1) TWI767148B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888268A (en) 1985-09-11 1989-12-19 Fuji Photo Film Co., Ltd. Silver halide photographic materials comprising blocked photographic reagants releasing plug groups
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
US5376664A (en) 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
DE69730607T2 (de) 1996-07-19 2005-01-27 Takeda Chemical Industries, Ltd. Fas ligand ähnliches protein, seine herstellung und verwendung
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
JP2002512368A (ja) 1998-04-23 2002-04-23 カロ バイオ ユー エス エイ，インコーポレイテッド 受容体の生物活性を調節するための化合物の能力を予測する方法
CA2334679C (en) 1998-06-11 2012-10-23 3-Dimensional Pharmaceuticals, Inc. Pyrazinone protease inhibitors
AU763460B2 (en) 1998-10-09 2003-07-24 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
CO5190665A1 (es) 1999-06-23 2002-08-29 Smithkline Beecham Corp Compuestos de indol
CO5180605A1 (es) 1999-06-23 2002-07-30 Smithkline Beecham Corp Compuestos de indol
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
WO2001014363A1 (en) 1999-08-23 2001-03-01 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2001014362A1 (en) 1999-08-23 2001-03-01 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AR029001A1 (es) 1999-08-23 2003-06-04 Smithkline Beecham Corp Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
AU6715200A (en) 1999-09-04 2001-04-10 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
US6486211B1 (en) 1999-10-22 2002-11-26 Smithkline Beecham Corporation Indole compounds
AU1607501A (en) 1999-11-15 2001-05-30 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
EP1255567A1 (en) 1999-11-15 2002-11-13 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
JP2003534340A (ja) 2000-05-24 2003-11-18 スミスクライン・ビーチャム・コーポレイション 脂肪酸シンターゼ阻害剤
EP1164374A1 (en) 2000-06-16 2001-12-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying apoptosis-modified proteins
EP1764616B1 (en) 2000-06-16 2009-04-08 Thomas Dr. Rudel Method for identifying apoptosis modified proteins
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
US6608059B1 (en) 2000-06-27 2003-08-19 Smithkline Beecham Corporation Fatty acid synthase inhibitors
US6670388B1 (en) 2000-06-27 2003-12-30 Smithkline Beecham Corporation Fatty acid synthase inhibitors
WO2002002119A1 (en) 2000-06-29 2002-01-10 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AU2001284705A1 (en) 2000-08-02 2002-02-13 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
JP2004505038A (ja) 2000-08-02 2004-02-19 スミスクライン・ビーチャム・コーポレイション 脂肪酸シンターゼ阻害剤
AU2001291160A1 (en) 2000-09-22 2002-04-02 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
CN1458933A (zh) 2000-09-29 2003-11-26 日本曹达株式会社 噻吩并嘧啶化合物及其盐以及其制备方法
JP2002201193A (ja) 2000-10-25 2002-07-16 Takeda Chem Ind Ltd 三環性化合物、その製造法および剤
AU2002243439A1 (en) 2000-11-17 2002-07-24 Smithkline Beecham Corporation Fatty acid synthase inhibitors
AU2002247847A1 (en) 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
AU2002258791A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
FR2829766A1 (fr) 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
US7309788B2 (en) 2001-09-21 2007-12-18 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
AU2002360561A1 (en) 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
EA007468B1 (ru) 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
CA2477657C (en) 2002-03-05 2011-04-26 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Cathepsin cysteine protease inhibitors
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
AU2003228674A1 (en) * 2002-04-26 2003-11-10 Schering Corporation Muscarinic antagonists
AU2003253925A1 (en) 2002-07-18 2004-02-09 Banyu Pharmaceutical Co., Ltd. Combination therapy for the treatment of obesity
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的噁二唑
JP3897662B2 (ja) 2002-08-26 2007-03-28 三井化学株式会社 光記録媒体
AU2003262023A1 (en) 2002-09-10 2004-04-30 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
AU2003218462A1 (en) 2002-10-01 2004-04-23 Merck And Co., Inc. Treatment of obesity and other disorders associated with excessive food intake
JP2006512404A (ja) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
EP1578414A4 (en) 2002-12-04 2007-10-24 Merck & Co Inc PHENYLALANINE DERIVATIVES ALSDIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
EP1591120A4 (en) 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
US20060148721A1 (en) 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
JP2006528180A (ja) 2003-07-22 2006-12-14 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としてのピペリジン誘導体
AU2004264724A1 (en) 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives for the treatment of HIV infections
TWI290140B (en) 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
WO2005073186A1 (ja) 2004-01-29 2005-08-11 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
SI1751131T1 (sl) 2004-03-10 2009-04-30 Janssen Pharmaceutica Nv MTP inhibirajoči aril piperidini ali piperazini substituirani s 5-členskimi heterocikli
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
MXPA06011167A (es) 2004-04-01 2007-01-25 Eli Lilli And Company Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
CA2562130C (en) 2004-04-12 2011-06-07 Torrent Pharmaceuticals Ltd. 2-propene-1-ones as hsp 70 inducers
CN1984901B (zh) 2004-05-18 2011-02-09 先灵公司 用作pde4抑制剂的取代的2-喹啉基-*唑
CN1997370B (zh) 2004-05-19 2011-06-01 索尔瓦药物有限公司 N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途
JP4891071B2 (ja) 2004-05-28 2012-03-07 独立行政法人理化学研究所 フラーレン誘導体の製造方法
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
EP1797084A1 (en) 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
WO2006049933A2 (en) 2004-10-29 2006-05-11 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
MX2007006695A (es) 2004-12-03 2007-08-14 Schering Corp Piperazinas sustituidas como antagonistas de cb1.
KR100637951B1 (ko) 2004-12-09 2006-10-26 엘지전자 주식회사 댁내의 전력 사용량 관리 시스템
GB2436261B (en) 2004-12-11 2010-06-09 Merck Patent Gmbh Liquid crystal compounds,liquid crystal medium and liquid crystal display
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
KR20080012304A (ko) 2005-05-23 2008-02-11 니뽄 다바코 산교 가부시키가이샤 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약
ES2337728T3 (es) 2005-06-20 2010-04-28 Schering Corporation Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3.
WO2007003962A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
ES2378153T3 (es) 2005-09-27 2012-04-09 Irm Llc Conpuestos y composiciones que contienen diarilamina, y su uso como moduladores de receptores c-kit
RU2416603C9 (ru) 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
AU2006337682A1 (en) 2005-11-14 2007-08-16 Irm Llc Compounds and compositions as LXR modulators
CN101326187A (zh) 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
CN101331131A (zh) 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
US7879880B2 (en) 2005-12-21 2011-02-01 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
AU2006327243A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
CA2634250A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
CN101374825A (zh) 2006-01-13 2009-02-25 霍夫曼-拉罗奇有限公司 环己基哌嗪基甲酮衍生物及它们作为组胺h3受体调节剂的应用
PE20070854A1 (es) 2006-01-20 2007-09-10 Schering Corp Compuestos heterociclos como agonistas del receptor de acido nicotinico
JP5031771B2 (ja) 2006-01-23 2012-09-26 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３受容体活性を有するシクロヘキシルスルホンアミド誘導体
EP1981341A4 (en) 2006-01-30 2011-01-05 Merck Sharp & Dohme FATTY ACID SYNTHESIS HEMMER (FAS)
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
KR20090015098A (ko) 2006-05-30 2009-02-11 에프. 호프만-라 로슈 아게 피페리디닐 피리미딘 유도체
WO2007138355A1 (en) 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
CN101535249A (zh) 2006-11-02 2009-09-16 塞诺菲-安万特德国有限公司 具有改善的药理性质的新的哌嗪-1-磺酸取代的二苯基氮杂环丁酮
WO2008059214A1 (en) 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
CN101190894A (zh) 2006-11-23 2008-06-04 中国人民解放军军事医学科学院毒物药物研究所 脂肪酸合成酶抑制剂及其制药用途
JP2010510987A (ja) 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
TW200833663A (en) 2006-12-21 2008-08-16 Astrazeneca Ab Therapeutic agents
DE102006060598A1 (de) 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
WO2008075077A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Piperidine derivatives for the treatment of obesity
JP2010513357A (ja) 2006-12-22 2010-04-30 ノバルティス アーゲー Ｄｐｐ−ｉｖ阻害剤としての１−アミノメチル−１−フェニル−シクロヘキサン誘導体
DE102007007751A1 (de) 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
WO2008106202A1 (en) 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
ES2369440T3 (es) 2007-02-28 2011-11-30 Conatus Pharmaceuticals, Inc. Método para el tratamiento de la hepatitis viral de tipo c crónica usando ro 113-0830.
WO2008106167A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2008109175A1 (en) 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
PT2142533E (pt) 2007-03-30 2012-01-19 Hoffmann La Roche Derivados de imidazolidinona
GB0707051D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
WO2008133955A1 (en) 2007-04-25 2008-11-06 Exelixis, Inc. 6-phenylpyrimidinones as pim modulators
ES2439255T3 (es) 2007-06-21 2014-01-22 Cara Therapeutics, Inc. Imidazoheterociclos sustituidos
EP2019091A1 (en) 2007-06-25 2009-01-28 Fundació Privada Institut d'Investigació Biomédica de Girona - Dr. Josep Trueta Novel polyhydroxylated compounds as Fatty Acid Synthase (FASN) inhibitors
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
JP5583579B2 (ja) 2007-08-29 2014-09-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 液晶ディスプレイ
JP2011519340A (ja) 2007-10-30 2011-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換アルカン酸調製のためのエナンチオ選択的プロセスこの米国特許正規出願は、２００７年１０月３０日に提出された米国特許仮出願第６１／００１，００４号、及び２００８年２月２９日に提出された米国特許仮出願第６１／０６７，８４２号の権利を主張する。
WO2009064927A2 (en) 2007-11-13 2009-05-22 Fasgen, Inc. Phosphorylated fatty acid synthase and cancer
CN101998959B (zh) 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
WO2009098282A1 (en) 2008-02-06 2009-08-13 Novasaid Ab Low molecular weight 2,5-disubstituted thiophene derivatives and use thereof in therapy
JP2011518774A (ja) 2008-03-20 2011-06-30 フォレスト・ラボラトリーズ・ホールディングス・リミテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤としての新規ピペリジン誘導体
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2009143404A1 (en) 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8349210B2 (en) 2008-06-27 2013-01-08 Transitions Optical, Inc. Mesogenic stabilizers
NZ591166A (en) 2008-08-06 2012-11-30 Biomarin Pharm Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
WO2010056631A1 (en) 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
JP5576874B2 (ja) 2008-11-14 2014-08-20 ザ スクリプス リサーチ インスティテュート モノアシルグリセロールリパーゼの薬物標的化と関連する方法及び組成物
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
WO2010077915A1 (en) 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
EP2361290B1 (de) 2008-12-22 2013-05-22 Merck Patent GmbH Flüssigkristallanzeige
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
DE102010006691A1 (de) 2009-02-06 2010-10-28 Merck Patent Gmbh Flüssigkristallines Medium und Flüssigkristallanzeige
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201041868A (en) 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
WO2010120262A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
US8173650B2 (en) 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
EP2445506B1 (en) 2009-06-24 2014-12-31 Entarco SA The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
KR101732205B1 (ko) 2009-08-28 2017-05-02 주식회사 쿠라레 Ｎ-아실-β-락탐 유도체, 고분자 화합물 및 포토레지스트 조성물
WO2011035018A2 (en) 2009-09-18 2011-03-24 Fate Therapeutics, Inc. Suicide ready cells
BR112012006802A2 (pt) 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
EP2485728B1 (en) 2009-10-07 2013-07-10 Siena Biotech S.p.a. Wnt pathway antagonists
US8759357B2 (en) 2009-10-08 2014-06-24 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
JP2013508461A (ja) 2009-10-27 2013-03-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール
EP2493910A1 (en) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JP2013512245A (ja) 2009-11-24 2013-04-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸合成酵素阻害剤としてのアザベンズイミダゾール
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
DE102010008644A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
SG183260A1 (en) 2010-02-22 2012-09-27 Glaxosmithkline Llc Triazolones as fatty acid synthase inhibitors
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2584899B1 (en) 2010-06-24 2018-01-10 Trustees Of Tufts College Niacin mimetics, and use thereof
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2616071A2 (en) 2010-09-17 2013-07-24 GlaxoSmithKline Intellectual Property Development Limited Fatty acid synthase inhibitors
EP2615918A4 (en) 2010-09-17 2014-01-29 Glaxosmithkline Ip Dev Ltd INHIBITORS OF ACID GRAS SYNTHASE
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
US20130237535A1 (en) 2010-11-08 2013-09-12 Nicholas D. Adams Fatty acid synthase inhibitors
WO2012064632A1 (en) 2010-11-12 2012-05-18 Wake Forest University Health Sciences Methods of treating cancer and other disorders
EP2655706A4 (en) 2010-11-24 2014-10-15 Gabrielle Ronnett METHODS OF SCREENING COMPOUNDS THAT ARE CYTOTOXIC FOR TUMOR CELLS AND METHODS OF TREATING TUMOR CELLS USING SUCH COMPOUND
JP2012123282A (ja) 2010-12-10 2012-06-28 Nikon Corp 電子機器
US20150232455A1 (en) 2010-12-15 2015-08-20 Allan C. Krueger Anti-viral compounds
US20150031884A1 (en) 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
EP2651920A4 (en) 2010-12-15 2014-12-17 Abbvie Inc ANTI-VIRAL COMPOUNDS
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012096928A2 (en) 2011-01-10 2012-07-19 Glaxosmithkline Llc Pyrimidinone derivatives as fatty acid synthase inhibitors
EP2668177B1 (en) 2011-01-28 2014-10-22 Boehringer Ingelheim International GmbH Substituted pyridinyl-pyrimidines and their use as medicaments
CN103492367B (zh) 2011-02-17 2015-04-01 拜耳知识产权有限责任公司 用于治疗的取代的3-(联苯-3-基)-8,8-二氟-4-羟基-1-氮杂螺[4.5]癸-3-烯-2-酮
HUE032459T2 (en) 2011-03-08 2017-09-28 3-V Biosciences Inc Heterocyclic modulators of lipid synthesis
CA2829123C (en) 2011-03-14 2016-04-12 Eternity Bioscience Inc. Quinazolinediones and their use
DE102012003796A1 (de) 2011-03-18 2012-09-20 Merck Patent Gmbh Flüssigkristallines Medium
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP2014516366A (ja) 2011-03-29 2014-07-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 液晶媒体
TWI527800B (zh) 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
AU2012250690B2 (en) 2011-05-03 2017-06-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
RU2675656C2 (ru) 2011-05-03 2018-12-21 Аджиос Фармасьютикалз, Инк. Способы применения активаторов пируваткиназы
KR20140030267A (ko) 2011-05-23 2014-03-11 사노피 Ｎ­알킬 그룹을 함유하는 중수소화된 화합물의 제조방법
CN107083243A (zh) 2011-07-07 2017-08-22 默克专利股份有限公司 液晶介质
DE102011080406A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one
JP5964426B2 (ja) * 2011-08-19 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 脂肪酸シンターゼ阻害剤
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
WO2013028445A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
SG2014011654A (en) 2011-08-30 2014-08-28 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013064083A1 (en) 2011-11-01 2013-05-10 Impact Therapeutics, Inc. 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
EP2809673B1 (en) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
US9822129B2 (en) * 2012-03-02 2017-11-21 Genentech, Inc. Amido spirocyclic amide and sulfonamide derivatives
CN102627610B (zh) 2012-04-11 2014-06-25 江苏先声药物研究有限公司 一类苯并咪唑类衍生物及其应用
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
CN103420890B (zh) 2012-05-15 2015-06-24 天津药物研究院 3-吡咯甲酸衍生物及其制备方法和用途
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9056860B2 (en) * 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
MA37830B1 (fr) * 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
US9526720B2 (en) 2012-08-17 2016-12-27 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
WO2014039769A1 (en) 2012-09-07 2014-03-13 Janssen Pharmaceutica Nv Imidazolin-5-one derivatives useful as fatty acid snthase (fasn) inhibitors for|the treatment of cancer
AR092211A1 (es) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung Derivados de hidropirrolopirrol
CN104837956B (zh) 2012-12-12 2018-01-30 默克专利股份有限公司 液晶介质
JP2014118368A (ja) 2012-12-14 2014-06-30 Taisho Pharmaceutical Co Ltd アザスピロアルカン化合物を有効成分として含有する血糖低下作用薬
PT2968316T (pt) 2013-03-13 2019-10-29 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenilfenil)carbonil]piperazin-1-il}etano-1-ona e compostos relacionados como inibidores da sintase de ácidos gordos (fasn) para o tratamento do cancro
US8940893B2 (en) * 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
CA2907657A1 (en) 2013-03-21 2014-09-25 Merck Patent Gmbh Piperazine derivatives as fasn inhibitors
WO2014166584A1 (de) 2013-04-08 2014-10-16 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung mit thermisch aktiviertem verzögertem fluoreszenzmaterial
JP6553022B2 (ja) 2013-04-08 2019-07-31 メルク パテント ゲーエムベーハー 有機エレクトロルミネッセント素子
SG11201600726QA (en) 2013-07-29 2016-03-30 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives
TWI648383B (zh) 2013-08-02 2019-01-21 德商馬克專利公司 液晶介質
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
CA2932396C (en) 2013-12-03 2022-03-29 Janssen Pharmaceutica Nv Benzamide derivative useful as fasn inhibitors for the treatment of cancer
KR20150070027A (ko) 2013-12-16 2015-06-24 메르크 파텐트 게엠베하 액정 매질
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
US9828364B2 (en) * 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
SG11201608242XA (en) 2014-04-04 2016-10-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3805218A1 (en) 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107205972A (zh) 2014-04-23 2017-09-26 X-Rx股份有限公司 自分泌运动因子的取代的n‑(2‑(氨基)‑2‑氧代乙基)苯甲酰胺抑制剂及它们的制备和在治疗lpa‑依赖的或lpa‑介导的疾病中的用途
MX2020010847A (es) 2014-05-13 2021-07-16 Hoffmann La Roche Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
WO2016005577A1 (en) 2014-07-11 2016-01-14 Intervet International B.V. Use of anthelmintic agents against dirofilaria immitis
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
CN106687563B (zh) 2014-09-05 2023-03-14 默克专利有限公司 制剂和电子器件
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP3195182B1 (en) 2014-09-16 2021-09-29 Verifone, Inc. Secure smartcard reader
KR20170090422A (ko) * 2014-10-31 2017-08-07 인디비어 유케이 리미티드 도파민 d3 수용체 길항제 화합물
MX2017009408A (es) 2015-01-20 2017-10-02 Merial Inc Compuestos antihelminticos, composiciones y metodo para usar los mismos.
CN104876912B (zh) 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
MX2017016370A (es) 2015-06-18 2018-04-11 Cephalon Inc Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
EP3112440B1 (en) 2015-07-02 2019-07-24 Merck Patent GmbH Liquid-crystal medium
WO2017019822A1 (en) 2015-07-29 2017-02-02 Medivation Technologies, Inc. Pellet composition containing repair cells
WO2017019817A1 (en) 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions for targeted therapeutics
JP2018534380A (ja) 2015-09-09 2018-11-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 液晶媒体
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
EP3297183A4 (en) 2015-12-21 2018-08-22 Mitsubishi Electric Corporation Optical relay device, control method, and optical transmission system
KR102419178B1 (ko) 2015-12-29 2022-07-11 삼성디스플레이 주식회사 유기 발광 소자
KR20170097820A (ko) 2016-02-18 2017-08-29 삼성디스플레이 주식회사 유기 발광 소자
CN109071455B (zh) * 2016-03-11 2022-08-02 嘉兴和剂药业有限公司 用于调节布鲁顿酪氨酸激酶的化合物及方法
HRP20230537T1 (hr) 2016-03-16 2023-08-04 Kura Oncology, Inc. Supstituirani derivati tieno[2,3-d]pirimidina kao inhibitori za menin-mll i postupci za uporabu
WO2017189613A1 (en) 2016-04-25 2017-11-02 Forma Therapeutics, Inc. Methods of using fasn inhibitors
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CA2939286A1 (en) * 2016-08-17 2018-02-17 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
US10930863B2 (en) 2016-11-04 2021-02-23 Samsung Electronics Co., Ltd. Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound
JP2019533714A (ja) 2016-11-11 2019-11-21 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脂質合成の複素環式モジュレーター
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CA3046805A1 (en) 2016-12-14 2018-06-21 89Bio Ltd. Spiropiperidine derivatives
CN106831787B (zh) * 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
CN109384790B (zh) * 2017-08-08 2022-05-10 药捷安康(南京)科技股份有限公司 成纤维细胞生长因子受体抑制剂及其用途
WO2020013752A1 (en) 2018-07-12 2020-01-16 Suncarbon Ab Lignin purification
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Also Published As

Publication number Publication date
BR112021005836A2 (pt) 2021-07-27
US11299484B2 (en) 2022-04-12
TW202026283A (zh) 2020-07-16
SG11202103454SA (en) 2021-05-28
US20210024508A1 (en) 2021-01-28
AR116626A1 (es) 2021-05-26
JP2022504730A (ja) 2022-01-13
KR20210075120A (ko) 2021-06-22
MX2021003992A (es) 2021-06-23
CA3116045A1 (en) 2020-04-16
US20220315565A1 (en) 2022-10-06
US20200115368A1 (en) 2020-04-16
AU2019357592A1 (en) 2021-05-06
IL282065A (en) 2021-05-31
CN113329748A (zh) 2021-08-31
TWI767148B (zh) 2022-06-11
US10875848B2 (en) 2020-12-29
MA51606A (fr) 2020-11-25

Similar Documents

Publication Publication Date Title
MX2023001917A (es) Inhibidores de la fosfatasa shp2 y metodos para su uso.
CR20200518A (es) Piridozinonas como inhibidores de parp7
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12017501888A1 (en) Bromodomain inhibitor
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
EA202091709A1 (ru) Ингибиторы днк-пк
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2021013146A (es) Inhibidores de receptores del factor de crecimiento de fibroblastos (fgfr) y metodos de uso de los mismos.
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
EA202091708A1 (ru) Ингибиторы днк-пк
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2020014303A (es) Inhibición de la proteína de union a creb (cbp).
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
AU2020258568A8 (en) CD73 inhibitors
EA202190902A1 (ru) Ингибирование синтазы жирных кислот (fasn)
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.